Whitehawk Therapeutics (WHWK) Insider Desai Buys 38,040 Shares

Neil Desai Buys Shares in Whitehawk Therapeutics

On June 12, 2026, Neil Desai joined a group of insiders purchasing shares in Whitehawk Therapeutics, Inc. WHWK on the NasdaqCM exchange. The transaction involved acquiring 38,040 shares of the clinical-stage oncology therapeutics company. This round of insider activity included several other key individuals making identical share purchases on the same date.

Recent Insider Activity Across the Board

This wave of insider purchases on June 12, 2026, featured several prominent names picking up shares alongside Neil Desai. Mohammad Hirmand bought 38,040 shares, Behzad Aghazadeh acquired 38,040 shares, and Baiteng Zhao picked up 38,040 shares. Additional insider buying came from Richard Maroun, Emma Reeve, and Caley Castelein, who each also acquired 38,040 shares of the biotech firm.

Stock Performance and Moving Averages

Whitehawk Therapeutics shares recently traded at $4.10, sitting just below the 50-day moving average of $4.29 and above the 200-day moving average of $3.71. The stock has traded between a 52-week low of $1.82 and a 52-week high of $5.50. With a market capitalization of roughly $230.3 million, the clinical-stage company operates without a traditional P/E ratio due to its current lack of profitability.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the company's progress in developing antibody drug conjugates for cancer treatments. On October 1, 2026, Stifel initiated coverage on the stock with a buy rating and a $9.00 price target. Earlier, Leerink Partners initiated an outperform rating with a $9.00 target on July 13, 2026, and B. Riley Securities set a buy rating with a $10.00 target on June 25, 2026. The overall analyst consensus sits at a buy, backed by six opinions and a mean price target of $7.50.

Inside Whitehawk Therapeutics

Whitehawk Therapeutics is a clinical-stage oncology company headquartered in Morristown, New Jersey, focused on developing next-generation antibody drug conjugates to treat cancer. Formerly known as Aadi Bioscience before changing its name in August 2021, the firm employs 32 people and advances technologies aimed at establishing tumor biology for patient treatments.

What to Watch at Whitehawk Therapeutics, Inc.

Investors will look toward the company's next earnings report, scheduled for November 5, 2026, for further updates on its clinical pipeline and financial position. Additional SEC filings will provide more clarity on whether insiders continue adding to their holdings as the clinical trials progress.